VPS35 (Vacuolar Protein Sorting-Associated Protein 35) is a core component of the retromer complex, a highly conserved protein assembly responsible for cargo recognition and endosomal protein recycling. By mediating the trafficking of membrane proteins from endosomes back to the Golgi or plasma membrane, VPS35 plays a crucial role in maintaining cellular homeostasis, receptor signaling, and lysosomal function. Mutations in VPS35—particularly the D620N variant—have been strongly linked to autosomal-dominant Parkinson’s disease, highlighting its importance in neuronal integrity and mitochondrial quality control.
In research settings, VPS35 is widely studied as a key regulator of endosomal sorting pathways and neurodegenerative disease mechanisms. It is frequently used as a biomarker to evaluate retromer function, α-synuclein trafficking, mitochondrial dynamics, and cellular stress responses. VPS35 expression and mutation analysis are also valuable tools in studies exploring proteinopathy, synaptic dysfunction, and age-related neuronal decline.
Clinically, VPS35 is most relevant as a genetic and mechanistic biomarker in Parkinson’s disease and other neurodegenerative disorders. Detection of pathogenic VPS35 mutations supports early identification of familial PD cases, while expression and functional assays help characterize disease progression and therapeutic response. As interest in retromer-stabilizing therapies grows, VPS35 continues to gain attention as both a diagnostic target and a potential lever for disease-modifying interventions.
This product is manufactured in Canada by StressMarq.
| Size | 1 x 96 Well |
| Sensitivity | 50 pg/mL |
| Dynamic Range | 78.125 – 5000 pg/mL |
| Incubation Time | 3 hours |
| Sample Type | Tissue, Cell Lysate |
| Storage | 2-8°C (-20°C components) |
| Alternative Names | FLJ10752, MEM3, PARK17, TCCCTA00141, VPS35 retromer complex component, Vacuolar protein sorting-associated protein 35, maternal-embryonic 3, vesicle protein sortin 35 |

